Massively parallel sequencing of tumors enables the identification of oncogenomic mutations that correlate with response and resistance to targeted therapies. This webinar presents the path followed by Memorial Sloan Kettering Cancer Center (MSKCC) to develop a hybridization-based capture panel encompassing more than 300 key cancer-associated genes, which they have applied to characterize several thousand tumors. Their translational research efforts will be discussed, including examples in which the speaker’s group has identified genomic biomarkers predictive of drug response in a variety of tumor types.

Meet the Speaker:

Dr. Michael Berger is an assistant attending in the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSKCC) and an affiliate member of MSKCC’s Human Oncology and Pathogenesis Program. He is also the associate director of the newly created Marie-Josée and Henry R. Kravis Center for Molecular Oncology at MSKCC, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the...




Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?